Skip to main content

Liminatus Pharma, Inc.

LIMN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001971387

No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $105.1K in total; no superinvestor holds it.

Other share classesLIMNW

13F holders, Q2 2025

Institutional positions in Liminatus Pharma, Inc. as of Jun 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
10
+10 vs. Q1 2025
Shares held
204.7K
+204.7K vs. Q1 2025
Total value
$2.28M
+$2.28M vs. Q1 2025
New holders
10
0 more added
Sold out
0
0 more reduced

Compare with Q1 2025: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting LIMN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ2 2025: 10 institutions
Q1 2021: 0 institutionsQ2 2021: 0 institutionsQ3 2021: 0 institutionsQ4 2021: 0 institutionsQ1 2022: 0 institutionsQ2 2022: 0 institutionsQ3 2022: 0 institutionsQ4 2022: 0 institutionsQ1 2023: 0 institutionsQ2 2023: 0 institutionsQ3 2023: 0 institutionsQ4 2023: 0 institutionsQ1 2024: 0 institutionsQ2 2024: 0 institutionsQ3 2024: 0 institutionsQ4 2024: 0 institutionsQ1 2025: 0 institutionsQ2 2025: 10 institutionsQ3 2025: 10 institutionsQ4 2025: 12 institutionsQ1 2026: 15 institutionsQ2 2026: 14 institutions
Value heldQ2 2025: $2.28M
Q1 2021: $0Q2 2021: $0Q3 2021: $0Q4 2021: $0Q1 2022: $0Q2 2022: $0Q3 2022: $0Q4 2022: $0Q1 2023: $0Q2 2023: $0Q3 2023: $0Q4 2023: $0Q1 2024: $0Q2 2024: $0Q3 2024: $0Q4 2024: $0Q1 2025: $0Q2 2025: $2.28MQ3 2025: $437.4KQ4 2025: $193.5KQ1 2026: $253.8KQ2 2026: $105.1K
Institutions holding LIMN and their total value by quarter
QuarterHoldersValue
Q2 202614$105.1K
Q1 202615$253.8K
Q4 202512$193.5K
Q3 202510$437.4K
Q2 202510$2.28M
Q1 20250$0
Q4 20240$0
Q3 20240$0
Q2 20240$0
Q1 20240$0
Q4 20230$0
Q3 20230$0
Q2 20230$0
Q1 20230$0
Q4 20220$0
Q3 20220$0
Q2 20220$0
Q1 20220$0
Q4 20210$0
Q3 20210$0
Q2 20210$0
Q1 20210$0

Institutions, Q2 2025

Shares, value and share of portfolio for each institution holding Liminatus Pharma, Inc.; share changes are against Q1 2025.

Institutions holding LIMN in Q2 2025
InstitutionSharesValue% of portfolioChange in sharesAction
Vanguard Group Inc73,424$818.7K0.00%+73,424New
Geode Capital Management, LLC63,841$711.8K0.00%+63,841New
UBS Group AG31,486$351.1K0.00%+31,486New
State Street Corp19,000$211.8K0.00%+19,000New
BlackRock, Inc.13,255$147.8K0.00%+13,255New
Royal Bank of Canada2,886$32.0K0.00%+2,886New
Tower Research Capital LLC (TRC)508$5.66K0.00%+508New
Barclays PLC184$2.05K0.00%+184New
Bank of America Corp66$7350.00%+66New
SBI Securities Co., Ltd.52$5800.00%+52New